» Articles » PMID: 31955209

Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry

Abstract

Context: Cardiovascular disease (CVD) is a major cause of mortality in adults with type 1 diabetes.

Objective: We prospectively evaluated CVD risk factors in a large, contemporary cohort of adults with type 1 diabetes living in the United States.

Design: Observational study of CVD and CVD risk factors over a median of 5.3 years.

Setting: The T1D Exchange clinic network.

Patients: Adults (age ≥ 18 years) with type 1 diabetes and without known CVD diagnosed before or at enrollment.

Main Outcome Measure: Associations between CVD risk factors and incident CVD were assessed by multivariable logistic regression.

Results: The study included 8,727 participants (53% female, 88% non-Hispanic white, median age 33 years [interquartile ratio {IQR} = 21, 48], type 1 diabetes duration 16 years [IQR = 9, 26]). At enrollment, median HbA1c was 7.6% (66 mmol/mol) (IQR = 6.9 [52], 8.6 [70]), 33% used a statin, and 37% used blood pressure medication. Over a mean follow-up of 4.6 years, 325 (3.7%) participants developed incident CVD. Ischemic heart disease was the most common CVD event. Increasing age, body mass index, HbA1c, presence of hypertension and dyslipidemia, increasing duration of diabetes, and diabetic nephropathy were associated with increased risk for CVD. There were no significant gender differences in CVD risk.

Conclusion: HbA1c, hypertension, dyslipidemia and diabetic nephropathy are important risk factors for CVD in adults with type 1 diabetes. A longer follow-up is likely required to assess the impact of other traditional CVD risk factors on incident CVD in the current era.

Citing Articles

Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes.

Saeed Z, Akturk H, Aleppo G, Kruger D, Levy C, Mader J Clin Diabetes. 2025; 43(1):131-138.

PMID: 39829697 PMC: 11739354. DOI: 10.2337/cd24-0067.


Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.

Shah V, Agesen R, Bardtrum L, Christiansen E, Snaith J, Greenfield J J Diabetes Sci Technol. 2024; 19(2):321-331.

PMID: 39717993 PMC: 11669135. DOI: 10.1177/19322968241305647.


Exploring the Physicochemical Characteristics of Marine Protein Hydrolysates and the Impact of In Vitro Gastrointestinal Digestion on Their Bioactivity.

Sharma D, Gite S, Tuohy M Mar Drugs. 2024; 22(10).

PMID: 39452860 PMC: 11509636. DOI: 10.3390/md22100452.


Unseen threat: how subclinical atherosclerosis increases mortality risk in patients with type 1 diabetes.

Sojo-Vega L, Recasens M, Martinez J, Aguilera A, Ayala M, Admetlla N Cardiovasc Diabetol. 2024; 23(1):366.

PMID: 39420367 PMC: 11488122. DOI: 10.1186/s12933-024-02455-0.


Strategies for Cardiovascular Disease Prevention in Type 1 Diabetes: A Comprehensive Review.

Ahuja A, Agrawal S, Acharya S, Reddy V, Batra N Cureus. 2024; 16(8):e66420.

PMID: 39246894 PMC: 11380626. DOI: 10.7759/cureus.66420.


References
1.
Eeg-Olofsson K, Gudbjornsdottir S, Eliasson B, Zethelius B, Cederholm J . The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract. 2014; 106(1):136-44. DOI: 10.1016/j.diabres.2014.07.010. View

2.
Snell-Bergeon J, Hokanson J, Jensen L, MacKenzie T, Kinney G, Dabelea D . Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003; 26(10):2923-8. DOI: 10.2337/diacare.26.10.2923. View

3.
Orchard T, Costacou T . Cardiovascular complications of type 1 diabetes: update on the renal link. Acta Diabetol. 2016; 54(4):325-334. DOI: 10.1007/s00592-016-0949-7. View

4.
Miller R, Costacou T, Orchard T . Risk Factor Modeling for Cardiovascular Disease in Type 1 Diabetes in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study: A Comparison With the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and.... Diabetes. 2018; 68(2):409-419. PMC: 6341302. DOI: 10.2337/db18-0515. View

5.
. 11. Microvascular Complications and Foot Care: . Diabetes Care. 2018; 42(Suppl 1):S124-S138. DOI: 10.2337/dc19-S011. View